EMEA-002028-PIP01-16-M02

Table of contents

Key facts

Invented name
Imfinzi
Active substance
durvalumab
Therapeutic area
Oncology
Decision number
P/0106/2021
PIP number
EMEA-002028-PIP01-16-M02
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
  • Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue)
  • Treatment of malignant neoplasms of lymphoid tissue
Route(s) of administration
Intravenous use
Contact for public enquiries
AstraZeneca AB

Tel. +46 8553 27591
E-mail: paediatrics@astrazeneca.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating